Roche Holding AG

SWX:ROP Stock Report

Market Cap: CHF 261.4b

Roche Holding Valuation

Is ROP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of ROP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: ROP (CHF319) is trading below our estimate of future cash flow value (CHF832.03)

Significantly Below Future Cash Flow Value: ROP is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ROP?

Key metric: As ROP is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ROP. This is calculated by dividing ROP's market cap by their current earnings.
What is ROP's PE Ratio?
PE Ratio19.7x
EarningsCHF 12.88b
Market CapCHF 261.36b

Price to Earnings Ratio vs Peers

How does ROP's PE Ratio compare to its peers?

The above table shows the PE ratio for ROP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average45.3x
NOVN Novartis
19.9x9.63%CHF 221.5b
GALD Galderma Group
82.2x24.31%CHF 40.5b
SDZ Sandoz Group
39.9x17.12%CHF 29.8b
DESN Dottikon ES Holding
39.5x26.55%CHF 4.1b
ROP Roche Holding
19.7x8.05%CHF 261.4b

Price-To-Earnings vs Peers: ROP is good value based on its Price-To-Earnings Ratio (19.7x) compared to the peer average (45.3x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does ROP's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
ROP 19.7xIndustry Avg. 21.4xNo. of Companies11PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ROP is good value based on its Price-To-Earnings Ratio (19.7x) compared to the European Pharmaceuticals industry average (21.4x).

Price to Earnings Ratio vs Fair Ratio

What is ROP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ROP PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19.7x
Fair PE Ratio35.7x

Price-To-Earnings vs Fair Ratio: ROP is good value based on its Price-To-Earnings Ratio (19.7x) compared to the estimated Fair Price-To-Earnings Ratio (35.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ROP forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 319.00
CHF 358.83
+12.49%
14.63%CHF 428.00CHF 230.00n/a18
Jun ’27CHF 317.40
CHF 360.76
+13.66%
14.80%CHF 428.00CHF 230.00n/a17
May ’27CHF 318.40
CHF 360.76
+13.31%
14.80%CHF 428.00CHF 230.00n/a17
Apr ’27CHF 318.30
CHF 352.00
+10.59%
12.57%CHF 415.00CHF 295.00n/a7
Mar ’27CHF 367.00
CHF 355.48
-3.14%
13.62%CHF 428.00CHF 230.00n/a19
Feb ’27CHF 350.70
CHF 351.30
+0.17%
13.60%CHF 428.00CHF 230.00n/a20
Jan ’27CHF 328.20
CHF 324.39
-1.16%
14.03%CHF 418.00CHF 230.00n/a18
Dec ’26CHF 309.00
CHF 307.56
-0.47%
15.12%CHF 418.00CHF 230.00n/a18
Nov ’26CHF 258.90
CHF 298.34
+15.23%
15.77%CHF 418.00CHF 230.00n/a18
Oct ’26CHF 282.30
CHF 299.82
+6.21%
17.09%CHF 438.00CHF 230.00n/a17
Sep ’26CHF 260.20
CHF 298.64
+14.77%
16.96%CHF 438.00CHF 230.00n/a18
Aug ’26CHF 257.10
CHF 300.29
+16.80%
15.93%CHF 438.00CHF 230.00n/a19
Jul ’26CHF 260.70
CHF 302.63
+16.08%
16.10%CHF 454.00CHF 220.00n/a20
Jun ’26CHF 265.50
CHF 302.63
+13.98%
16.10%CHF 454.00CHF 220.00CHF 317.4020
May ’26CHF 269.30
CHF 305.08
+13.29%
16.12%CHF 454.00CHF 220.00CHF 318.4020
Apr ’26CHF 292.40
CHF 315.03
+7.74%
14.50%CHF 448.00CHF 230.00CHF 318.3020
Mar ’26CHF 299.20
CHF 309.37
+3.40%
15.54%CHF 448.00CHF 230.00CHF 367.0020
Feb ’26CHF 286.00
CHF 305.60
+6.85%
15.74%CHF 438.00CHF 230.00CHF 350.7019
Jan ’26CHF 255.50
CHF 303.36
+18.73%
16.62%CHF 440.00CHF 230.00CHF 328.2018
Dec ’25CHF 255.50
CHF 302.25
+18.30%
16.89%CHF 440.00CHF 220.00CHF 309.0018
Nov ’25CHF 273.10
CHF 303.76
+11.23%
17.04%CHF 438.00CHF 220.00CHF 258.9017
Oct ’25CHF 265.00
CHF 302.00
+13.96%
17.32%CHF 440.00CHF 220.00CHF 282.3018
Sep ’25CHF 287.20
CHF 295.63
+2.94%
17.07%CHF 440.00CHF 220.00CHF 260.2019
Aug ’25CHF 285.80
CHF 287.74
+0.68%
17.11%CHF 440.00CHF 220.00CHF 257.1019
Jul ’25CHF 250.10
CHF 278.58
+11.39%
20.43%CHF 428.00CHF 210.00CHF 260.7019
Jun ’25CHF 231.00
CHF 277.53
+20.14%
20.54%CHF 428.00CHF 210.00CHF 265.5019
CHF 358.83
Fair Value
11.1% undervalued intrinsic discount
18
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/18 10:33
End of Day Share Price 2026/06/18 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Roche Holding AG is covered by 44 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John StaszakArgus Research Company
Gerhard SchwarzBaader Helvea Equity Research
Mark PurcellBarclays